Samsung Biologics Co Ltd (207940) - Total Assets
Based on the latest financial reports, Samsung Biologics Co Ltd (207940) holds total assets worth ₩18.34 Trillion KRW (≈ $12.43 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 207940 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Samsung Biologics Co Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore how much of Samsung Biologics Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Samsung Biologics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Samsung Biologics Co Ltd's total assets of ₩18.34 Trillion consist of 31.8% current assets and 68.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.3% |
| Accounts Receivable | ₩0.00 | 0.0% |
| Inventory | ₩2.82 Trillion | 16.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩3.89 Trillion | 22.4% |
| Goodwill | ₩1.68 Trillion | 9.7% |
Asset Composition Trend (2014–2024)
This chart illustrates how Samsung Biologics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 207940 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Samsung Biologics Co Ltd's current assets represent 31.8% of total assets in 2024, an increase from 16.0% in 2014.
- Cash Position: Cash and equivalents constituted 2.3% of total assets in 2024, down from 7.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 22.4% of total assets.
Samsung Biologics Co Ltd Competitors by Total Assets
Key competitors of Samsung Biologics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Samsung Biologics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.69 | 1.35 | 2.97 |
| Quick Ratio | 0.86 | 0.60 | 1.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩2.59 Trillion | ₩1.25 Trillion | ₩1.16 Trillion |
Samsung Biologics Co Ltd - Advanced Valuation Insights
This section examines the relationship between Samsung Biologics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.53 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.0% |
| Total Assets | ₩17.34 Trillion |
| Market Capitalization | $31.37 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Samsung Biologics Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Samsung Biologics Co Ltd's assets grew by 8.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Samsung Biologics Co Ltd (2014–2024)
The table below shows the annual total assets of Samsung Biologics Co Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩17.34 Trillion ≈ $11.75 Billion |
+8.04% |
| 2023-12-31 | ₩16.05 Trillion ≈ $10.87 Billion |
-3.23% |
| 2022-12-31 | ₩16.58 Trillion ≈ $11.24 Billion |
+108.06% |
| 2021-12-31 | ₩7.97 Trillion ≈ $5.40 Billion |
+24.06% |
| 2020-12-31 | ₩6.42 Trillion ≈ $4.35 Billion |
+8.67% |
| 2019-12-31 | ₩5.91 Trillion ≈ $4.01 Billion |
-1.15% |
| 2018-12-31 | ₩5.98 Trillion ≈ $4.05 Billion |
-16.74% |
| 2017-12-31 | ₩7.18 Trillion ≈ $4.87 Billion |
-4.65% |
| 2016-12-31 | ₩7.53 Trillion ≈ $5.11 Billion |
+26.38% |
| 2015-12-31 | ₩5.96 Trillion ≈ $4.04 Billion |
+339.66% |
| 2014-12-31 | ₩1.36 Trillion ≈ $918.74 Million |
-- |
About Samsung Biologics Co Ltd
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line de… Read more